At the news
? BULLISHIMPACT 8/10 DEFA14A filed Jun 25, 2026 at 16:46 ET
Bio-Techne has entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash. The deal is expected to close by late 2026 or early 2027, subject to shareholder and regulatory approvals. This definitive additional proxy soliciting material communicates the terms and seeks support for the merger.
- Acquisition price: $73.00 per share in cash
- Expected close: late 2026 or early 2027
- Subject to shareholder approval and regulatory approvals
- Employee stock options and RSUs will be cashed out at $73.00 per share
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access